Sanofi-Aventis (SNY) discontinues clinical trials of its controversial anti-obesity drug which...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi-Aventis (SNY) discontinues clinical trials of its controversial anti-obesity drug which had been linked to psychiatric side effects. Separately, Pfizer (PFE) and Merck (MRK) have both abandoned similar drugs.